## Nicholas R Leslie

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/62686/publications.pdf

Version: 2024-02-01

83 papers 8,307 citations

45 h-index 80 g-index

86 all docs

86 docs citations

86 times ranked 11775 citing authors

#	Article	IF	Citations
1	The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins. Journal of Cell Biology, 2004, 166, 213-223.	5.2	1,013
2	Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO Journal, 2003, 22, 5501-5510.	7.8	536
3	PTEN function: how normal cells control it and tumour cells lose it. Biochemical Journal, 2004, 382, 1-11.	3.7	448
4	PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. Journal of Clinical Investigation, 2008, 118, 3762-3774.	8.2	403
5	PTEN: The down side of PI 3-kinase signalling. Cellular Signalling, 2002, 14, 285-295.	3.6	393
6	GSK3 and its interactions with the PI3K/AKT/mTOR signalling network. Advances in Biological Regulation, 2017, 65, 5-15.	2.3	328
7	Three-dimensional bioprinting of complex cell laden alginate hydrogel structures. Biofabrication, 2015, 7, 045012.	7.1	320
8	Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO Journal, 2009, 28, 1505-1517.	7.8	302
9	Mechanisms of PTEN loss in cancer: It's all about diversity. Seminars in Cancer Biology, 2019, 59, 66-79.	9.6	214
10	3D Printing in Suspension Baths: Keeping the Promises of Bioprinting Afloat. Trends in Biotechnology, 2020, 38, 584-593.	9.3	183
11	PtdIns(3,4,5)P3-Dependent and -Independent Roles for PTEN in the Control of Cell Migration. Current Biology, 2007, 17, 115-125.	3.9	178
12	Phosphorylation by Akt within the ST loop of AMPK- $\hat{l}\pm 1$ down-regulates its activation in tumour cells. Biochemical Journal, 2014, 459, 275-287.	3.7	176
13	Small Molecule Antagonists of the Ïf-1 Receptor Cause Selective Release of the Death Program in Tumor and Self-Reliant Cells and Inhibit Tumor Growth in Vitro and in Vivo. Cancer Research, 2004, 64, 4875-4886.	0.9	164
14	Prostate cancer, PI3K, PTEN and prognosis. Clinical Science, 2017, 131, 197-210.	4.3	146
15	The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif. Biochemical Journal, 2004, 379, 301-307.	3.7	144
16	Hypomorphic Mutation of PDK1 Suppresses Tumorigenesis in PTEN+/â^' Mice. Current Biology, 2005, 15, 1839-1846.	3.9	141
17	PTEN is destabilized by phosphorylation on Thr366. Biochemical Journal, 2007, 405, 439-444.	3.7	140
18	Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear pool that is insensitive to PTEN expression. Journal of Cell Science, 2006, 119, 5160-5168.	2.0	137

#	Article	IF	CITATIONS
19	Non-genomic loss of PTEN function in cancer: not in my genes. Trends in Pharmacological Sciences, 2011, 32, 131-140.	8.7	137
20	TPIP: a novel phosphoinositide 3-phosphatase. Biochemical Journal, 2001, 360, 277-283.	3.7	136
21	The Redox Regulation of PI 3-Kinase–Dependent Signaling. Antioxidants and Redox Signaling, 2006, 8, 1765-1774.	5.4	134
22	MC1R Is a Potent Regulator of PTEN after UV Exposure in Melanocytes. Molecular Cell, 2013, 51, 409-422.	9.7	122
23	Phosphoinositide-Regulated Kinases and Phosphoinositide Phosphatases. Chemical Reviews, 2001, 101, 2365-2380.	47.7	112
24	PTEN Protein Phosphatase Activity Correlates with Control of Gene Expression and Invasion, a Tumor-Suppressing Phenotype, But Not with AKT Activity. Science Signaling, 2012, 5, ra18.	3.6	107
25	Leptin Regulates AMPA Receptor Trafficking via PTEN Inhibition. Journal of Neuroscience, 2010, 30, 4088-4101.	3.6	104
26	A novel leptin signalling pathway via PTEN inhibition in hypothalamic cell lines and pancreatic $\hat{l}^2$ -cells. EMBO Journal, 2006, 25, 2377-2387.	7.8	103
27	Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes. Journal of Medical Genetics, 2015, 52, 128-134.	3.2	99
28	Use of Akt Inhibitor and a Drug-resistant Mutant Validates a Critical Role for Protein Kinase B/Akt in the Insulin-dependent Regulation of Glucose and System A Amino Acid Uptake. Journal of Biological Chemistry, 2008, 283, 27653-27667.	3.4	96
29	TPIP: a novel phosphoinositide 3-phosphatase. Biochemical Journal, 2001, 360, 277.	3.7	95
30	Differential redox regulation within the PTP superfamily. Cellular Signalling, 2007, 19, 1521-1530.	3.6	89
31	MyosinV controls PTEN function and neuronal cell size. Nature Cell Biology, 2009, 11, 1191-1196.	10.3	82
32	Inherited PTEN mutations and the prediction of phenotype. Seminars in Cell and Developmental Biology, 2016, 52, 30-38.	5.0	78
33	Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signalling pathways downstream of phosphoinositide 3-kinase. Biochemical Journal, 2000, 346, 827-833.	3.7	74
34	Cross Talk between the Akt and p38 $\hat{l}$ $\pm$ Pathways in Macrophages Downstream of Toll-Like Receptor Signaling. Molecular and Cellular Biology, 2013, 33, 4152-4165.	2.3	74
35	Chemoresistant KM12C Colon Cancer Cells Are Addicted to Low Cyclic AMP Levels in a Phosphodiesterase 4–Regulated Compartment via Effects on Phosphoinositide 3-Kinase. Cancer Research, 2007, 67, 5248-5257.	0.9	68
36	Class I PI 3-kinases: Function and evolution. Advances in Biological Regulation, 2015, 59, 53-64.	2.3	66

#	Article	IF	CITATIONS
37	Three dimensional in vitro models of cancer: Bioprinting multilineage glioblastoma models. Advances in Biological Regulation, 2020, 75, 100658.	2.3	66
38	Detection of novel intracellular agonist responsive pools of phosphatidylinositol 3,4-bisphosphate using the TAPP1 pleckstrin homology domain in immunoelectron microscopy. Biochemical Journal, 2004, 377, 653-663.	3.7	63
39	Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions. Biochemical Journal, 2001, 357, 427-435.	3.7	61
40	PTEN inhibitors: An evaluation of current compounds. Advances in Biological Regulation, 2015, 57, 102-111.	2.3	57
41	PTEN Methylation by NSD2 Controls Cellular Sensitivity to DNA Damage. Cancer Discovery, 2019, 9, 1306-1323.	9.4	54
42	A Unified Nomenclature and Amino Acid Numbering for Human PTEN. Science Signaling, 2014, 7, pe15.	3.6	50
43	A role for the actin cytoskeleton in the hormonal and growth-factor-mediated activation of protein kinase B. Biochemical Journal, 2000, 352, 617-622.	3.7	49
44	The significance of PTEN's protein phosphatase activity. Advances in Enzyme Regulation, 2009, 49, 190-196.	2.6	47
45	PtdIns(4,5)P2-Mediated Cell Signaling: Emerging Principles and PTEN as a Paradigm for Regulatory Mechanism. Advances in Experimental Medicine and Biology, 2013, 991, 85-104.	1.6	46
46	Stimulation of PI 3-kinase signaling via inhibition of the tumor suppressor phosphatase, PTEN. Advances in Enzyme Regulation, 2007, 47, 184-194.	2.6	45
47	Ubiquitination of PTEN (Phosphatase and Tensin Homolog) Inhibits Phosphatase Activity and Is Enhanced by Membrane Targeting and Hyperosmotic Stress. Journal of Biological Chemistry, 2010, 285, 12620-12628.	3.4	45
48	The PTEN protein: cellular localization and post-translational regulation. Biochemical Society Transactions, 2016, 44, 273-278.	3.4	43
49	Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions. Biochemical Journal, 2001, 357, 427.	3.7	40
50	Cloning and characterisation of hAps1 and hAps2, human diadenosine polyphosphate-metabolising Nudix hydrolases. BMC Biochemistry, 2002, 3, 20.	4.4	39
51	Phosphorylation of the Actin Binding Protein Drebrin at S647 Is Regulated by Neuronal Activity and PTEN. PLoS ONE, 2013, 8, e71957.	2.5	33
52	$\hat{I}^21$ -Integrin and PTEN control the phosphorylation of protein kinase C. Biochemical Journal, 2000, 352, 425-433.	3.7	31
53	Distinct inactivation of PI3K signalling by PTEN and 5-phosphatases. Advances in Biological Regulation, 2012, 52, 205-213.	2.3	30
54	C1-Ten Is a Protein Tyrosine Phosphatase of Insulin Receptor Substrate 1 (IRS-1), Regulating IRS-1 Stability and Muscle Atrophy. Molecular and Cellular Biology, 2013, 33, 1608-1620.	2.3	29

#	Article	IF	CITATIONS
55	A simple and robust real-time qPCR method for the detection of PIK3CA mutations. Scientific Reports, 2018, 8, 4290.	3.3	28
56	A Screen for Novel Phosphoinositide 3-kinase Effector Proteins. Molecular and Cellular Proteomics, 2011, 10, M110.003178.	3.8	26
57	PTEN M-CBR3, a Versatile and Selective Regulator of Inositol 1,3,4,5,6-Pentakisphosphate (Ins(1,3,4,5,6)P5). Journal of Biological Chemistry, 2004, 279, 1116-1122.	3.4	25
58	IQGAP Proteins Reveal an Atypical Phosphoinositide (aPI) Binding Domain with a Pseudo C2 Domain Fold. Journal of Biological Chemistry, 2012, 287, 22483-22496.	3.4	23
59	Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signalling pathways downstream of phosphoinositide 3-kinase. Biochemical Journal, 2000, 346, 827.	3.7	22
60	Identification of a PTEN mutation with reduced protein stability, phosphatase activity, and nuclear localization in Hong Kong patients with autistic features, neurodevelopmental delays, and macrocephaly. Autism Research, 2018, 11, 1098-1109.	3.8	22
61	The PTEN and Myotubularin Phosphoinositide 3-Phosphatases: Linking Lipid Signalling to Human Disease. Sub-Cellular Biochemistry, 2012, 58, 281-336.	2.4	16
62	Decreased insulin binding to mononuclear leucocytes and erythrocytes from dogs after S-nitroso-N-acetypenicillamine administration. BMC Biochemistry, 2002, 3, 1.	4.4	15
63	PIK3CA mutation enrichment and quantitation from blood and tissue. Scientific Reports, 2020, 10, 17082.	3.3	15
64	Substrate specificity and acute regulation of the tumour suppressor phosphatase, PTEN. Biochemical Society Symposia, 2007, 74, 69-80.	2.7	14
65	Controlling PTEN (Phosphatase and Tensin Homolog) Stability. Journal of Biological Chemistry, 2016, 291, 18465-18473.	3.4	14
66	Indirect mechanisms of carcinogenesis via downregulation of PTEN function. Advances in Enzyme Regulation, 2010, 50, 112-118.	2.6	13
67	Mutant PTEN in Cancer: Worse Than Nothing. Cell, 2014, 157, 527-529.	28.9	13
68	Yeast-based methods to assess PTEN phosphoinositide phosphatase activity in vivo. Methods, 2015, 77-78, 172-179.	3.8	13
69	Migration Stimulating Factor (MSF) promotes fibroblast migration by inhibiting AKT. Cellular Signalling, 2010, 22, 1655-1659.	<b>3.</b> 6	11
70	PTEN: An Intercellular Peacekeeper?. Science Signaling, 2012, 5, pe50.	3.6	11
71	Where Is PTEN?. Science, 2013, 341, 355-356.	12.6	10
72	Assaying PTEN catalysis in vitro. Methods, 2015, 77-78, 51-57.	3.8	9

#	Article	IF	CITATIONS
73	In Cell and In Vitro Assays to Measure PTEN Ubiquitination. Methods in Molecular Biology, 2016, 1388, 155-165.	0.9	7
74	P-REX2a Driving Tumorigenesis by PTEN Inhibition. Science Signaling, 2009, 2, pe68.	3.6	6
75	Mechanism of Activation of PKB/Akt by the Protein Phosphatase Inhibitor Calyculin A. Cell Biochemistry and Biophysics, 2010, 58, 147-156.	1.8	6
76	SWAP70 undergoes dynamic conformational regulation at the leading edge of migrating cells. FEBS Letters, 2019, 593, 395-405.	2.8	6
77	Microfluidic system for near-patient extraction and detection of miR-122 microRNA biomarker for drug-induced liver injury diagnostics. Biomicrofluidics, 2022, 16, 024108.	2.4	6
78	Assays to Measure PTEN Lipid Phosphatase Activity In Vitro from Purified Enzyme or Immunoprecipitates. Methods in Molecular Biology, 2016, 1447, 95-105.	0.9	2
79	Importin-11 keeps PTEN safe from harm. Journal of Cell Biology, 2017, 216, 539-541.	5.2	1
80	Phosphoinositide-Dependent Protein Kinases. , 2021, , .		1
81	Phosphoinositide-Dependent Protein Kinases. , 2004, , 292-296.		O
82	Kinases/Phosphatases   Phosphoinositide-Dependent Protein Kinases. , 2021, , 369-372.		0
83	PTEN., 2018,, 4274-4279.		O